Q2 Earnings Estimate for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Investment analysts at B. Riley issued their Q2 2025 EPS estimates for shares of TG Therapeutics in a research note issued on Tuesday, March 4th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will earn $0.27 per share for the quarter. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $1.03 EPS, FY2027 earnings at $2.78 EPS, FY2028 earnings at $3.85 EPS and FY2029 earnings at $4.74 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million.

TGTX has been the subject of several other reports. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.67.

Remove Ads

TG Therapeutics Stock Performance

Shares of TGTX stock traded down $1.68 during mid-day trading on Friday, reaching $37.55. The stock had a trading volume of 3,801,786 shares, compared to its average volume of 2,638,415. TG Therapeutics has a one year low of $12.93 and a one year high of $40.31. The firm has a market cap of $5.90 billion, a PE ratio of -375.46 and a beta of 2.30. The firm's 50 day simple moving average is $31.23 and its 200 day simple moving average is $28.67. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

Institutional Trading of TG Therapeutics

Hedge funds have recently modified their holdings of the company. Bleakley Financial Group LLC bought a new stake in TG Therapeutics during the 4th quarter worth approximately $245,000. Castellan Group bought a new stake in shares of TG Therapeutics during the fourth quarter worth $8,539,000. Oppenheimer & Co. Inc. bought a new stake in shares of TG Therapeutics during the third quarter worth $759,000. Segall Bryant & Hamill LLC acquired a new stake in shares of TG Therapeutics in the third quarter valued at $1,225,000. Finally, Barclays PLC raised its holdings in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after buying an additional 158,323 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Activity

In related news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.50% of the stock is owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.